Ziftomenib clinical trials
Also written KO-539.
How each study uses ziftomenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ziftomenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 13 Nov 2025 · KOMZIFTI · NDA 220305 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2025 (5); 1 more planned to start later
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 9
Kura Oncology, Inc. (5) · M.D. Anderson Cancer Center (4) · Massachusetts General Hospital (2) · Tanja Andrea Gruber (1) · Uma Borate (1) · PedAL BCU, LLC (1) · Kyowa Kirin Co., Ltd. (1)
Often tested with
Tested in the same studies.
Olutasidenib (1) · Venetoclax (1) · Azacitidine (1) · Daunorubicin (1) · Cytarabine (1) · Mezigdomide (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test ziftomenib.
- Dec 2026Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPhase 1 · Kura Oncology, Inc.
- Jan 2027Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid LeukemiaPhase 1 · M.D. Anderson Cancer Center
- Mar 2027A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid LeukemiaPhase 2 · Kyowa Kirin Co., Ltd.
- Apr 2027Ziftomenib Maintenance Post Allo-HCTPhase 1 · Massachusetts General Hospital
- Jul 2027Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AMLPhase 1 · Massachusetts General Hospital
Studies
Open first, then newest update. How each study uses ziftomenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIRecruitingPhase 1/2Tanja Andrea GruberNCT05848687Written as Ziftomenib
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLRecruitingPhase 3Kura Oncology, Inc.NCT07007312Written as Ziftomenib
- Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDSNot yet recruitingPhase 1Kura Oncology, Inc.NCT07929740Written as Ziftomenib
- Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard TherapyRecruitingPhase 2Uma BorateNCT06930352Written as Ziftomenib
- A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingPhase 1Kura Oncology, Inc.NCT06655246Written as ziftomenib
- Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute LeukemiaRecruitingPhase 1PedAL BCU, LLCNCT06376162Written as Ziftomenib
- Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AMLRecruitingPhase 1Massachusetts General HospitalNCT07355335Written as Ziftomenib
- Ziftomenib Maintenance Post Allo-HCTRecruitingPhase 1Massachusetts General HospitalNCT06440135Written as Ziftomenib
- Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid LeukemiaRecruitingPhase 1M.D. Anderson Cancer CenterNCT06769490Written as Ziftomenib
- A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute LeukemiasRecruitingPhase 1M.D. Anderson Cancer CenterNCT06397027Written as Ziftomenib
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingPhase 1Kura Oncology, Inc.NCT06001788Written as Ziftomenib
- A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaRecruitingPhase 1M.D. Anderson Cancer CenterNCT06448013Written as Ziftomenib
- A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid LeukemiaRecruitingPhase 2Kyowa Kirin Co., Ltd.NCT07623616Written as ziftomenib
- Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid LeukemiaActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT07411586Written as Ziftomenib
- First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingPhase 1/2Kura Oncology, Inc.NCT04067336Written as Ziftomenib
Given beside what is tested · 1 — ziftomenib is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call ziftomenib · ClinicalTrials.gg INT002179
- MeSH (NLM) C000731960ziftomenibOne source NLM
- UNII (FDA) 4MOD1F4ENCZIFTOMENIBConfirmed FDA, NLM, Wikidata
- Wikidata Q133521494ziftomenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C164227ZiftomenibOne source FDA
- DrugBank DB17171One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731960 | ziftomenib | One source NLM |
| UNII (FDA) | 4MOD1F4ENC | ZIFTOMENIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q133521494 | ziftomenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C164227 | Ziftomenib | One source FDA |
| DrugBank | DB17171 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.